Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno‐Oncology and Beyond: Challenges, Perspectives, and Prospects-Reference-Cited by-同舟云学术

Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno‐Oncology and Beyond: Challenges, Perspectives, and Prospects

Published:2020-08-02 Issue:6 Volume:108 Page:1156-1170
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Dai Haiqing Isaac¹^ORCID,Vugmeyster Yulia¹,Mangal Naveen¹

Affiliation:

1. Clinical Pharmacology/Quantitative Pharmacology/Translational Medicine EMD Serono (a business of Merck KGaA, Darmstadt, Germany) Billerica MA USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.1953

Reference81 articles.

1. Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology

2. European Medicines Agency.Dose–response information to support drug registration E4: ICH Harmonised Tripartite Guidelines (1994).

3. US Food and Drug Administration.Guidance for industry: exposure–response relationships‐study design data analysis and regulatory applications (2003).

4. Exposure-Response Analysis of Nivolumab in Patients With Previously Treated or Untreated Advanced Melanoma

5. Exposure–Response Analysis of Overall Survival for Tremelimumab in Unresectable Malignant Mesothelioma: The Confounding Effect of Disease Status

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Population Pharmacokinetics and Exposure-Response Analysis of Durvalumab in Combination with Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer;2024-08-26

2. Pharmacokinetics of trastuzumab and its efficacy and safety in HER2-positive cancer patients;Cancer Chemotherapy and Pharmacology;2024-08-23

3. Model‐informed Evidence for Clinical Non‐inferiority of Every‐2‐Weeks Versus Standard Weekly Dosing Schedule of Cetuximab in Metastatic Colorectal Cancer;Clinical Pharmacology & Therapeutics;2024-08-12

4. Mirikizumab Exposure–Response Relationships in Patients with Moderately‐to‐Severely Active Ulcerative Colitis in Randomized Phase II and III Studies;Clinical Pharmacology & Therapeutics;2024-05-26

5. Population pharmacokinetics and exposure–response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study;CPT: Pharmacometrics & Systems Pharmacology;2024-04-15